v3.26.1
Goodwill (Details)
₨ in Millions, $ in Millions
 12 Months Ended
Mar. 31, 2026
INR (₨)
Mar. 31, 2025
INR (₨)
Mar. 31, 2026
USD ($)
Disclosure of reconciliation of changes in goodwill [abstract]      
Opening balance, gross ₨ 28,758 ₨ 21,201  
Goodwill arising on business combinations [1] 0 7,377  
Effect of changes in foreign exchange rates 1,083 180  
Impairment loss [2] (16,948) (16,948)  
Closing balance ₨ 12,893 ₨ 11,810 $ 137
[1] Refer to Note 35 of these consolidated financial statements for details regarding goodwill arising on business combinations.
[2] The impairment loss of Rs.16,948 includes the following: · Rs.16,003 pertaining to the Company’s German subsidiary, betapharm Arzneimittel GmbH, which is part of the Company’s Global Generics segment. This impairment loss was recorded for the years ended March 31, 2009 and 2010; and · Rs.272 pertaining to the Company’s Nimbus Heath business, which is part of the Company’s Global Generics segment. This impairment loss was recorded for the year ended March 31, 2023.